Catalyst Pharmaceuticals (CPRX) Raw Materials (2023 - 2026)

Catalyst Pharmaceuticals has reported Raw Materials for 4 years, with the latest figure at $16.9 million in Q1 2026.

• For the quarter ending Q1 2026, Raw Materials rose 127.02% year-over-year to $16.9 million; the trailing twelve-month figure through Mar 2026 stood at $16.9 million (up 127.02% YoY), and the FY2025 full-year result was $17.1 million, up 162.92% from the prior year.
• Raw Materials for Q1 2026 stood at $16.9 million, down from $17.1 million in the prior quarter.
• The five-year high for Raw Materials was $17.1 million in Q4 2025, with the low at $1.9 million in Q4 2023.
• Historically, Raw Materials has averaged $8.9 million across 4 years, with a median of $6.9 million in 2024.
• Annual changes were most pronounced in 2024 — Raw Materials surged 241.26% — and 2025, when it declined 7.34%.
• Catalyst Pharmaceuticals' Raw Materials stood at $1.9 million in 2023, then surged by 241.26% to $6.5 million in 2024, then jumped by 162.92% to $17.1 million in 2025, then declined by 1.51% to $16.9 million in 2026.
• The last three Raw Materials figures came in at $16.9 million (Q1 2026), $17.1 million (Q4 2025), and $12.1 million (Q3 2025), per Business Quant data.